Acinar Cell Carcinoma

NEW YORK--( BUSINESS WIRE )--Delcath Systems, Inc. (Nasdaq: DCTH) (“Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of an independent study conducted by investigators at the University Hospital of Leipzig, Germany, in the European Society for Medical Oncology journal of Gastrointestinal Oncology. The study, titled “Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation,” highlights the efficacy and safety of repeated chemosaturation treatments using Delcath’s CHEMOSAT ® Hepatic Delivery System. Key Findings from the Independent Study: Patient Population: This retrospective study evaluated the efficacy of CHEMOSAT in 33 previously treated patients with unresectable intrahepatic metastases from various cancers: uveal melanoma (N=19), cholangiocarcinoma (N=8), hepatocellular carcinoma (N=2), and one patient each with ciliary body melanoma, acinar cell carcinoma, pancreatic cancer, or tonsil cancer (N=4). In addition to hepatic metastases, 7 out of 33 patients also had limited extrahepatic disease, which was found not to significantly impact overall survival. Disease Control Rate: The study reported a disease control rate (DCR) of 91%, with 30 out of 33 patients experiencing either objective tumor response or stable disease. Notably, 6 patients (18.2%) achieved complete response (CR) in the liver, including 5 patients with uveal melanoma and 1 patient with cholangiocarcinoma, who received a median of 5 treatment cycles. Hepatic Progression-Free Survival: Median hepatic progression-free survival (hPFS) was 52 weeks across all patients, with particularly strong outcomes for specific cancers: 69 weeks (16 months) median hPFS in patients with uveal melanoma. 38 weeks (8.5 months) median hPFS in patients with cholangiocarcinoma. Importance of Repeated Treatments: The investigators’ approach of using CHEMOSAT in the form of regularly repeated treatment cycles as clinically indicated (Figure 1), similar to systemic chemotherapy, resulted in long-term disease control in the majority of patients and was well tolerated. Tolerability and Safety: The safety profile of CHEMOSAT was consistent with published literature. Most patients experienced transient hematological adverse events, which were routinely managed with supportive care. Importantly, no significant liver damage was reported, even in patients who underwent multiple treatment cycles. Treatment was discontinued in 2 patients due to adverse events, and 2 patients withdrew consent during the treatment period. Dr. Vojislav Vukovic, Chief Medical Officer of Delcath Systems, commented, “The results of this independent study reinforce the potential of our CHEMOSAT Hepatic Delivery System as an essential tool in the management of primary and secondary liver tumors, particularly for patients with limited treatment options. The high rate of disease control observed, even in patients with extrahepatic tumor spread, underscores the importance of continuing to explore and refine this treatment approach in larger, prospective trials.” The publication is available here . About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. In the United States, HEPZATO KIT is considered a combination drug and device product and is regulated and approved for sale as a drug by the FDA. HEPZATO KIT is comprised of the chemotherapeutic drug melphalan and Delcath's proprietary Hepatic Delivery System (HDS). The HDS is used to isolate the hepatic venous blood from the systemic circulation while simultaneously filtrating hepatic venous blood during melphalan infusion and washout. The use of the HDS results in loco-regional delivery of a relatively high melphalan dose, which can potentially induce a clinically meaningful tumor response with minimal hepatotoxicity and reduce systemic exposure. HEPZATO KIT is approved in the United States as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease, or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. Please see the full Prescribing Information , including BOXED WARNING for the HEPZATO KIT. In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan, or CHEMOSAT, where it has been used in the conduct of percutaneous hepatic perfusion procedures at major medical centers to treat a wide range of cancers of the liver.

DUBLIN--( BUSINESS WIRE )--The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for prostate cancer care reached $35.3 billion in 2022. This market is expected to reach $56.4 billion by the end of 2028, growing at a CAGR of 8.3% from 2023 through 2028. As the second most diagnosed male cancer in the world, prostate cancer affects roughly 1.4 million people and kills more than 370,000 men each year, which represents about 4% of all cancer deaths worldwide. This cancer ranges from being a non-aggressive, slow-growing type that can do without treatment to an aggressive, fast-growing disease that needs intervention and timely treatment. Hence, early detection/screening, diagnosis and staging of prostate cancer are critical. The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028. It is estimated that over 60% of age-eligible men remain unscreened for prostate cancer. A large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for non-invasive biomarker tests in the prostate cancer screening market. The global market for prostate cancer pharmaceuticals was valued at $16.0 billion in 2022 and is expected to reach $29.6 billion by the end of 2028, at a CAGR of 11.0% during the forecast period. Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs. The direct cost for radical prostatectomy was estimated at $3.6 billion in 2022. This cost is expected to rise to $4.8 billion by the end of 2028. The growing popularity of robot-assisted laparoscopic prostatectomy (RALP) is expected to impact the overall radical prostatectomy market. Improved screening programs will result in an increase in radical prostatectomies, as this procedure is preferred in early detection stages. The radiotherapy device market is expected to grow as the incidence of prostate cancer worldwide continues to increase and better and more accurate imaging technologies combined with precise treatment strategies are developed. This market is expected to reach $2.2 billion by the end of 2028. This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report. The Report Includes 31 data tables and 63 additional tables An overview of the global market for the technologies for prevention and treatment of prostate cancer Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028 Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies Profiles of leading market participants Key Attributes: Report Attribute Details No. of Pages 157 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $37.9 Billion Forecasted Market Value (USD) by 2028 $56.4 Billion Compound Annual Growth Rate 8.3% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Prostate Cancer Biology of Prostate Cancer Symptoms Screening Diagnosis Localized Prostate Cancer Metastatic Prostate Cancer Watchful Waiting or Active Surveillance Treatment Chapter 4 Market Dynamics Market Drivers Increasing Prevalence of Prostate Cancer Active Surveillance and Screening Personalized Care Approvals for Metastatic Castration-Resistant Prostate Cancer Collaborations and Licensing Agreements Market Challenges Loss of Exclusivity and Genericization Shortage of Care Providers and Other Resources Market Opportunities Chapter 5 Screening and Diagnosis Market by Test Type Biomarker Tests PSA Tests Limitations of PSA Tests Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings Digital Rectal Exam Limitations of DREs Prostate Biopsy Grade (Gleason Score) of Prostate Cancer Prostatic Intraepithelial Neoplasia Atypical Small Acinar Proliferation Proliferative Inflammatory Atrophy Intraductal Carcinoma of the Prostate Limitations of Prostate Biopsies Imaging Technologies for Prostate Cancer Market for Prostate Cancer Screening/Diagnosis, by Test Type Biomarker Tests DREs Prostate Biopsies Chapter 6 Pharmaceuticals Market by Drug Type Hormone Therapy Androgen Deprivation Therapy Antiandrogen Therapies Hormone Therapy Uses in Prostate Cancer Treatment Targeted Therapy PARP Inhibitors Radioligand Therapies Small Molecule Targeted Agents Monoclonal Antibodies Chemotherapy Immunotherapy Market Revenue, by Drug Type Hormone Therapy Targeted Therapy Immunotherapy Chemotherapy Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type Active Surveillance Radical Prostatectomy Robotic Prostatectomy Open Radical Prostatectomy Laparoscopic Prostatectomy Radical Prostatectomy Market Revenue Radiation Therapy External Beam Radiation Therapy Brachytherapy Combined Radiation Therapy Radiation Therapy Device Market Revenue Chapter 8 Market Breakdown by Region Chapter 9 Emerging Technologies and Developments Liquid Biopsy Multiparametric MRI Homologous Recombination Repair Gene Mutation Advanced Radiotherapy Techniques AI and Machine Learning Chapter 10 Pipeline Analysis Chapter 11 Competitive Intelligence Screening and Diagnosis Market Market for Radiation Therapy Devices Pharmaceuticals Market Chapter 12 Company Profiles Abbott Accuray Astellas Pharma Astrazeneca Bayer Danaher Corp. Dendreon Pharmaceuticals Elekta F. Hoffmann-La Roche Johnson & Johnson Services Pfizer Sanofi Siemens Healthineers For more information about this report visit https://www.researchandmarkets.com/r/wra8q3 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for prostate cancer care reached $35.3 billion in 2022. This market is expected to reach $56.4 billion by the end of 2028, growing at a CAGR of 8.3% from 2023 through 2028. As the second most diagnosed male cancer in the world, prostate cancer affects roughly 1.4 million people and kills more than 370,000 men each year, which represents about 4% of all cancer deaths worldwide. This cancer ranges from being a non-aggressive, slow-growing type that can do without treatment to an aggressive, fast-growing disease that needs intervention and timely treatment. Hence, early detection/screening, diagnosis and staging of prostate cancer are critical. The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028. It is estimated that over 60% of age-eligible men remain unscreened for prostate cancer. A large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for non-invasive biomarker tests in the prostate cancer screening market. The global market for prostate cancer pharmaceuticals was valued at $16.0 billion in 2022 and is expected to reach $29.6 billion by the end of 2028, at a CAGR of 11.0% during the forecast period. Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs. The direct cost for radical prostatectomy was estimated at $3.6 billion in 2022. This cost is expected to rise to $4.8 billion by the end of 2028. The growing popularity of robot-assisted laparoscopic prostatectomy (RALP) is expected to impact the overall radical prostatectomy market. Improved screening programs will result in an increase in radical prostatectomies, as this procedure is preferred in early detection stages. The radiotherapy device market is expected to grow as the incidence of prostate cancer worldwide continues to increase and better and more accurate imaging technologies combined with precise treatment strategies are developed. This market is expected to reach $2.2 billion by the end of 2028. This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report. The Report Includes 31 data tables and 63 additional tables An overview of the global market for the technologies for prevention and treatment of prostate cancer Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028 Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies Profiles of leading market participants Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Prostate Cancer Biology of Prostate Cancer Symptoms Screening Diagnosis Localized Prostate Cancer Metastatic Prostate Cancer Watchful Waiting or Active Surveillance Treatment Chapter 4 Market Dynamics Market Drivers Increasing Prevalence of Prostate Cancer Active Surveillance and Screening Personalized Care Approvals for Metastatic Castration-Resistant Prostate Cancer Collaborations and Licensing Agreements Market Challenges Loss of Exclusivity and Genericization Shortage of Care Providers and Other Resources Market Opportunities Chapter 5 Screening and Diagnosis Market by Test Type Biomarker Tests PSA Tests Limitations of PSA Tests Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings Digital Rectal Exam Limitations of DREs Prostate Biopsy Grade (Gleason Score) of Prostate Cancer Prostatic Intraepithelial Neoplasia Atypical Small Acinar Proliferation Proliferative Inflammatory Atrophy Intraductal Carcinoma of the Prostate Limitations of Prostate Biopsies Imaging Technologies for Prostate Cancer Market for Prostate Cancer Screening/Diagnosis, by Test Type Biomarker Tests DREs Prostate Biopsies Chapter 6 Pharmaceuticals Market by Drug Type Hormone Therapy Androgen Deprivation Therapy Antiandrogen Therapies Hormone Therapy Uses in Prostate Cancer Treatment Targeted Therapy PARP Inhibitors Radioligand Therapies Small Molecule Targeted Agents Monoclonal Antibodies Chemotherapy Immunotherapy Market Revenue, by Drug Type Hormone Therapy Targeted Therapy Immunotherapy Chemotherapy Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type Active Surveillance Radical Prostatectomy Robotic Prostatectomy Open Radical Prostatectomy Laparoscopic Prostatectomy Radical Prostatectomy Market Revenue Radiation Therapy External Beam Radiation Therapy Brachytherapy Combined Radiation Therapy Radiation Therapy Device Market Revenue Chapter 8 Market Breakdown by Region Chapter 9 Emerging Technologies and Developments Liquid Biopsy Multiparametric MRI Homologous Recombination Repair Gene Mutation Advanced Radiotherapy Techniques AI and Machine Learning Chapter 10 Pipeline Analysis Chapter 11 Competitive Intelligence Screening and Diagnosis Market Market for Radiation Therapy Devices Pharmaceuticals Market Chapter 12 Company Profiles Abbott Accuray Astellas Pharma Astrazeneca Bayer Danaher Corp. Dendreon Pharmaceuticals Elekta F. Hoffmann-La Roche Johnson & Johnson Services Pfizer Sanofi Siemens Healthineers For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets